[Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2025)]. [PDF]
Infectiology Group +6 more
europepmc +1 more source
[Assessment Value of Short-Term Prognosis of Six Predictive Models for Patients with Acute-on-Chronic Liver Failure Treated with Artificial Liver Support System]. [PDF]
Ma YJ, Du LY, Bai L, Tang H.
europepmc +1 more source
[The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)]. [PDF]
Hematological Oncology Committee of China Anti-Cancer Association +5 more
europepmc +1 more source
[Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma]. [PDF]
Wang T, Wang WT.
europepmc +1 more source
[Chinese expert consensus on the diagnosis and treatment of human immunodeficiency virus infection related diffuse large B cell lymphoma (2025)]. [PDF]
Lymphoid Disease Group +5 more
europepmc +1 more source
[The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)]. [PDF]
Chinese Society of Lymphoma +3 more
europepmc +1 more source
Value of serum tryptophan in stratified management of 90-day mortality risk in patients with hepatitis B virus-related acute-on-chronic liver failure: a multicenter retrospective study. [PDF]
Zhou C +9 more
europepmc +1 more source
Tc17细胞对乙肝相关慢加急性肝衰竭病情进展及乙肝病毒清除的影响
【目的】探讨Tc17细胞表达对乙肝相关慢加急性肝衰竭(HBV-ACLF)病情进展及乙肝病毒清除的影响。【方法】纳入43例HBV-ACLF患者,以20例慢性乙型肝炎患者(CHB)和12例健康体检者(NC)为对照,流式细胞术检测外周血中Tc17细胞的表达,荧光定量PCR法检测HBV-DNA载量,采用MELD、MELD-Na、CLIF-CACLF及AARC评分等指标评估患者病情,分析Tc17细胞表达对病情进展及乙肝病毒清除的影响。【结果】与NC组及CHB组比较,HBV-ACLF患者Tc17细胞表达明显升高 ...
doaj
Expression and localization of HBsAg in corneas from HBsAg<b>-</b>seropositive donors preserved in medium<b>-</b>term preservation solution and glycerol. [PDF]
Ren H +7 more
europepmc +1 more source
[Prognosis and risk factors for mortality in cirrhotic patients with probable spontaneous bacterial peritonitis]. [PDF]
Tang Q +10 more
europepmc +1 more source

